167 related articles for article (PubMed ID: 33606890)
1. Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
Chien HC; Morreall D; Patil V; Rasmussen KM; Yong CM; Li CY; Passey DG; Burningham Z; Sauer BC; Halwani AS
Am J Hematol; 2021 Jun; 96(6):E184-E187. PubMed ID: 33606890
[No Abstract] [Full Text] [Related]
2. Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?
Zinzani PL; Tani M; Alinari L; Stefoni V; Baccarani M
Leuk Res; 2003 May; 27(5):465-6. PubMed ID: 12620298
[No Abstract] [Full Text] [Related]
3. [Therapy of Waldenström´s macroglobulinaemia in the year 2014].
Adam Z; Krejčí M; Pour L; Ševčíková E
Vnitr Lek; 2014 Feb; 60(2):139-57. PubMed ID: 24754419
[TBL] [Abstract][Full Text] [Related]
4. Alkylating Agents in the Treatment of Waldenström Macroglobulinemia.
Buske C
Hematol Oncol Clin North Am; 2018 Oct; 32(5):821-827. PubMed ID: 30190020
[TBL] [Abstract][Full Text] [Related]
5. [Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Adam Z; Pour L; Krejčí M; Ševčíková S; Pourová E; Ševčíková E; Král Z; Mayer J
Vnitr Lek; 2016 Jan; 62(1):25-39. PubMed ID: 26967234
[TBL] [Abstract][Full Text] [Related]
6. Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib.
Castillo JJ; LaMacchia J; Flynn CA; Sarosiek S; Pozdnyakova O; Treon SP
Br J Haematol; 2021 Nov; 195(3):466-468. PubMed ID: 34355802
[No Abstract] [Full Text] [Related]
7. Rituximab plus cyclophosphamide and dexamethasone
Xiong W; Lyu R; Yu Y; Wang T; Yan Y; Wang Y; Liu W; An G; Deng S; Xu Y; Sui W; Huang W; Zou D; Wang J; Qiu L; Yi S
Haematologica; 2024 May; 109(5):1614-1618. PubMed ID: 38205507
[No Abstract] [Full Text] [Related]
8. [Osteonecrosis developing after rituximab-containing chemotherapy for Waldenström macroglobulinemia].
Nakamura F; Hirai R; Higo T; Togano T; Sekine R
Rinsho Ketsueki; 2018; 59(3):305-309. PubMed ID: 29618689
[TBL] [Abstract][Full Text] [Related]
9. Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis.
Kim JL; Gerrie AS; Savage KJ; Villa D; Scott D; Craig JW; Farinha P; Skinnider B; Slack G; Connors JM; Sehn LH; Venner C; Freeman CL
Leuk Lymphoma; 2024 Mar; 65(3):346-352. PubMed ID: 38156444
[TBL] [Abstract][Full Text] [Related]
10. Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life.
Mulas O; Caocci G; Dessì D; Mantovani D; Moi G; Cabras MG; La Nasa G
Acta Haematol; 2021; 144(3):322-326. PubMed ID: 32892194
[TBL] [Abstract][Full Text] [Related]
11. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
Leblond V; Johnson S; Chevret S; Copplestone A; Rule S; Tournilhac O; Seymour JF; Patmore RD; Wright D; Morel P; Dilhuydy MS; Willoughby S; Dartigeas C; Malphettes M; Royer B; Ewings M; Pratt G; Lejeune J; Nguyen-Khac F; Choquet S; Owen RG
J Clin Oncol; 2013 Jan; 31(3):301-7. PubMed ID: 23233721
[TBL] [Abstract][Full Text] [Related]
12. Waldenström macroglobulinemia: my way.
Gertz M
Leuk Lymphoma; 2013 Mar; 54(3):464-71. PubMed ID: 22860921
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
[TBL] [Abstract][Full Text] [Related]
14. Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study.
Kabadi SM; Byfield SD; LE L; Olufade T
Anticancer Res; 2021 Feb; 41(2):927-936. PubMed ID: 33517299
[TBL] [Abstract][Full Text] [Related]
15. Evaluating treatment strategies in advanced Waldenström macroglobulinemia: use of quality-adjusted survival analysis.
Lévy V; Porcher R; Leblond V; Fermand JP; Cazin B; Maloisel F; Harousseau JL; Remenieras L; Guibon O; Chevret S;
Leukemia; 2001 Sep; 15(9):1466-70. PubMed ID: 11516109
[TBL] [Abstract][Full Text] [Related]
16. Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO).
Laribi K; Poulain S; Willems L; Merabet F; Le Calloch R; Eveillard JR; Herbaux C; Roos-Weil D; Chaoui D; Roussel X; Tricot S; Dupuis J; Dartigeas C; Bareau B; Bene MC; Baugier de Materre A; Leblond V
Br J Haematol; 2019 Jul; 186(1):146-149. PubMed ID: 30548257
[No Abstract] [Full Text] [Related]
17. [Polychimiotherapy and Waldenström's macroglobulinemia (author's transl)].
Barrier J; Grolleau JY; Renault JJ; Ozanne P; Bouret O
Sem Hop; 1979 Dec 8-15; 55(41-42):1925-6. PubMed ID: 231315
[TBL] [Abstract][Full Text] [Related]
18. Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas.
Olszewski AJ; Reagan JL; Castillo JJ
Am J Hematol; 2018 Jan; 93(1):E1-E3. PubMed ID: 28960532
[No Abstract] [Full Text] [Related]
19. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]